Abstract
Sorafenib is a small orally available multikinase inhibitor which is approved for the treatment of advanced renal cancer and hepatocellular carcinoma and is one of the first agents in molecular targeted therapy that was brought into clinical trials for metastatic melanoma patients. It blocks tumor proliferation by targeting the vascular endothelial growth factor receptors, platelet-derived growth factor receptors, RAF1, BRAF and probably other receptors involved in signal transduction in tumor cells (1). It is not exactly understood which targets of the above are the most relevant ones in the therapy of advanced melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
